Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 18/20 | 0.90 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | TSHR | P16473 | 2/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | FAP | Q12884 | 1/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.58 |
| ▸ | RECQL | P46063 | 1/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4668801 | 1.00 | DPP4 (0.90) | DPP4CYP3A4ALDH1A1TSHRLMNA | |
| SCHEMBL4075402 | 1.00 | DPP4 (0.90) | DPP4CYP3A4ALDH1A1TSHRLMNA | |
| SCHEMBL4667775 | 0.95 | DPP4 (1.00) | DPP4CYP3A4FAP | |
| SCHEMBL555347 | 0.95 | DPP4 (1.00) | DPP4CYP3A4FAP | |
| SCHEMBL4668611 | 0.94 | DPP4 (0.95) | DPP4CYP3A4FAP | |
| SCHEMBL4667656 | 0.89 | DPP4 (0.90) | DPP4CYP3A4 | |
| SCHEMBL4668939 | 0.89 | DPP4 (0.90) | DPP4CYP3A4 | |
| SCHEMBL14569260 | 0.88 | DPP4 (0.72) | DPP4ALDH1A1TSHRLMNAMAPT | |
| SCHEMBL14439100 | 0.88 | DPP4 (0.72) | DPP4ALDH1A1TSHRLMNAMAPT | |
| SCHEMBL14439070 | 0.88 | DPP4 (0.72) | DPP4ALDH1A1TSHRLMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7192952-B2 | Heterocyclic compounds that are inhibitors of the enzyme DPP-IV | NOVO NORDISK, A/S (DK) | 2007-03-20 | — | — | US | claimed |
| EP-1496877-B1 | METHOD AND COMPOSITION FOR TREATMENT OF DIABETES, HYPERTENSION, CHRONIC HEART FAILURE AND FLUID RETENTIVE STATES | NOVO NORDISK AS (DK) | 2008-10-01 | — | — | EP | disclosed |
| EP-1496877-B1 | METHOD AND COMPOSITION FOR TREATMENT OF DIABETES, HYPERTENSION, CHRONIC HEART FAILURE AND FLUID RETENTIVE STATES | NOVO NORDISK AS (DK) | 2008-10-01 | — | — | EP | disclosed |
| EP-1404675-B1 | DPP-IV-INHIBITING PURINE DERIVATIVES FOR THE TREATMENT OF DIABETES | NOVO NORDISK AS (DK) | 2008-03-12 | — | — | EP | disclosed |
| EP-1404675-B1 | DPP-IV-INHIBITING PURINE DERIVATIVES FOR THE TREATMENT OF DIABETES | NOVO NORDISK AS (DK) | 2008-03-12 | — | — | EP | disclosed |
| US-20070197552-A1 | Method and composition for treatment of diabetes, hypertension, chronic heart failure and fluid retentive states | NOVO NORDISK A/S (DK) | 2007-08-23 | — | — | US | disclosed |
| US-20070197552-A1 | Method and composition for treatment of diabetes, hypertension, chronic heart failure and fluid retentive states | NOVO NORDISK A/S (DK) | 2007-08-23 | — | — | US | disclosed |
| US-7192952-B2 | Heterocyclic compounds that are inhibitors of the enzyme DPP-IV | NOVO NORDISK, A/S (DK) | 2007-03-20 | — | — | US | disclosed |
| US-7192952-B2 | Heterocyclic compounds that are inhibitors of the enzyme DPP-IV | NOVO NORDISK, A/S (DK) | 2007-03-20 | — | — | US | disclosed |
| US-7192952-B2 | Heterocyclic compounds that are inhibitors of the enzyme DPP-IV | NOVO NORDISK, A/S (DK) | 2007-03-20 | — | — | US | disclosed |
| US-20050148606-A1 | Heterocyclic compounds that are inhibitors of the enzyme DPP-IV | KANSTRUP ANDERS B (DK) | 2005-07-07 | — | — | US | disclosed |
| US-6869947-B2 | Heterocyclic compounds that are inhibitors of the enzyme DPP-IV | NOVO NORDISK A/S (DK) | 2005-03-22 | — | — | US | disclosed |
| EP-1496877-A2 | METHOD AND COMPOSITION FOR TREATMENT OF DIABETES, HYPERTENSION, CHRONIC HEART FAILURE AND FLUID RETENTIVE STATES | NOVO NORDISK A/S (DK) | 2005-01-19 | — | — | EP | disclosed |
| WO-2004033455-A2 | HEMISUCCINATE SALTS OF HETEROCYCLIC DPP-IV INHIBITORS | NOVO NORDISK A/S (DK) | 2004-04-22 | — | — | WO | disclosed |
| WO-2004033455-A2 | HEMISUCCINATE SALTS OF HETEROCYCLIC DPP-IV INHIBITORS | NOVO NORDISK A/S (DK) | 2004-04-22 | — | — | WO | disclosed |
| EP-1404675-A1 | DPP-IV-INHIBITING PURINE DERIVATIVES FOR THE TREATMENT OF DIABETES | NOVO NORDISK A/S (DK) | 2004-04-07 | — | — | EP | disclosed |
| US-20030236272-A1 | Method and composition for treatment of diabetes, hypertension, chronic heart failure and fluid retentive states | NOVO NORDISK A/S (DK) | 2003-12-25 | — | — | US | disclosed |
| WO-2003057200-A2 | COMPOSITIONS COMPRISING INHIBITORS OF DPP-IV AND NEP ENZYMES FOR THE TREATMENT OF DIABETES | NOVO NORDISK A/S (DK) | 2003-07-17 | — | — | WO | disclosed |
| US-20030105077-A1 | Heterocyclic compounds that are inhibitors of the enzyme DPP-IV | NOVO NORDISK A/S (DK) | 2003-06-05 | — | — | US | disclosed |
| WO-2003004496-A1 | DPP-IV-INHIBITING PURINE DERIVATIVES FOR THE TREATMENT OF DIABETES | NOVO NORDISK A/S (DK) | 2003-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050148606-A1 | Heterocyclic compounds that are inhibitors of the enzyme DPP-IV | DPP4, DPP7, DPP3 | DPP4 1/4885CYP3A4 59/4885ALDH1A1 176/4885 |
| US-20030105077-A1 | Heterocyclic compounds that are inhibitors of the enzyme DPP-IV | DPP4, DPP7, DPP3 | DPP4 1/4885CYP3A4 67/4885ALDH1A1 55/4885 |
| US-20030236272-A1 | Method and composition for treatment of diabetes, hypertension, chronic heart failure and fluid retentive states | DPP4, GIPR, GLP1R | DPP4 1/4885CYP3A4 2557/4885ALDH1A1 2283/4885 |
| US-20070197552-A1 | Method and composition for treatment of diabetes, hypertension, chronic heart failure and fluid retentive states | DPP4, GIPR, GLP1R | DPP4 1/4885CYP3A4 2557/4885ALDH1A1 2283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.